Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Therapeutic Drug Monitoring

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FTD.0b013e3181816214PMID 18641540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting.

  2005cited by this paper
• Quantification of Lean Bodyweight

  2005cited by this paper
• Naloxone in opioid poisoning: walking the tightrope

  2005cited by this paper
• Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection.

  2005cited by this paper
• Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose

  2005cited by this paper
• Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

  2004cited by this paper
• Intranasal drug delivery: an alternative to intravenous administration in selected emergency cases.

  2004cited by this paper
• Adverse events after naloxone treatment of episodes of suspected acute opioid overdose

  2004cited by this paper
• Estimating impossible curves using NONMEM.

  2003cited by this paper
• I NTRANASAL A DMINISTRATION OF N ALOXONE BY P ARAMEDICS

  2002cited by this paper
• Diagnostic errors in an accident and emergency department

  2002cited by this paper
• Nasal administration of opioids for pain management in adults

  2002cited by this paper
• Ways to Fit a PK Model with Some Data Below the Quantification Limit

  2001cited by this paper
• Intranasal midazolam for childhood seizures.

  1998cited by this paper
• Determination of naloxone in human plasma by high-performance liquid chromatography with coulometric detection.

  1996cited by this paper
• The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'.

  1995cited by this paper
• Pulmonary edema following naloxone administration in a healthy orthopedic patient.

  1995cited by this paper
• Effects of Naloxone Infusions in Patients with the Pruritus of Cholestasis: A Double-Blind, Randomized, Controlled Trial

  1995cited by this paper
• Nasal administration of naloxone is as effective as the intravenous route in opiate addicts.

  1994cited by this paper
• Nasal administration of naloxone for detection of opiate dependence.

  1992cited by this paper
• The safety of prehospital naloxone administration by paramedics.

  1990cited by this paper
• Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction.

  1989cited by this paper
• Naloxone use: side effects may occur.

  1988cited by this paper
• Naloxone-induced pulmonary edema.

  1987cited by this paper
• A dosing nomogram for continuous infusion intravenous naloxone.

  1986cited by this paper
• Nasal absorption of naloxone and buprenorphine in rats

  1984cited by this paper
• Possible dangers of naloxone use.

  1982cited by this paper
• Potency, duration of action and pA2 in man of intravenous naloxone measured by reversal of morphine-depressed respiration.

  1981cited by this paper
• The Relationship of Pharmacokinetics to Pharmacological Activity: Morphine, Methadone and Naloxone

  1976cited by this paper
• Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action

  1976cited by this paper
• Disposition of naloxone: use of a new radioimmunoassay.

  1975cited by this paper
• Disposition of naloxone-7,8,3H in normal and narcotic-dependent men.

  1973cited by this paper
• Absorption and distribution of naloxone in rats after oral and intravenous administration

  1973cited by this paper
• Abortion and distribution of naloxone in rats after oral and intravenous administration.

  1973cited by this paper

• Clinical toxicity of nitazene detections in two Australian emergency department toxicosurveillance systems.

  2025cites this paper
• The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder

  2025cites this paper
• Intranasal Naloxone During Recurrent Exercise in Individuals with Type‐1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure–Response

  2025cites this paper
• A Case Report of Delayed Opioid Toxidrome After Administration of Naloxone

  2024cites this paper
• Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT.

  2024cites this paper
• Effectiveness of intramuscular naloxone 1,600 μg in addition to titrated intravenous naloxone 100 μg for opioid poisoning: a randomised controlled trial

  2024cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Naloxone

  2024cites this paper
• High-Dose Naloxone Formulations Are Not as Essential as We Thought

  2023cites this paper
• Dove: Shoulder-Based Opioid Overdose Detection and Reversal Device

  2023cites this paper
• Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization

  2023cites this paper
• Intranasal transmucosal drug delivery: An alternative approach to the parenteral route for medical emergencies

  2023cites this paper
• Re-examining Naloxone Pharmacokinetics After Intranasal and Intramuscular Administration Using the Finite Absorption Time Concept

  2023cites this paper
• Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021.

  2023cites this paper
• Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest

  2023cites this paper
• Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics

  2022cites this paper
• Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults

  2022cites this paper
• Acute Opioid Withdrawal Following Intramuscular Administration of Naloxone 1.6 mg: A Prospective Out-Of-Hospital Series.

  2022cites this paper
• Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics

  2021cites this paper
• Microneedle-mediated transdermal delivery of naloxone hydrochloride for treatment of opioid overdose.

  2021cites this paper
• Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study

  2020cites this paper
• Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data

  2020cites this paper
• Pharmacokinetics Of Transbuccal Swab-Administered Naloxone-HCl Using A Novel Plant-Based Resin Formulation In Dogs

  2020cites this paper
• A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children.

  2020cites this paper
• High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design

  2020cites this paper
• Letter in Reply.

  2020cites this paper
• Response to Do Patients Require Emergency Department Interventions After Prehospital Naloxone?

  2020cites this paper
• Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level

  2020cites this paper
• One single large intramuscular dose of naloxone is effective and safe in suspected heroin poisoning

  2020cites this paper
• Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs.

  2019cites this paper
• The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence.

  2019cites this paper
• Simultaneous quantification of high-dose naloxone and naloxone-3-β-d-glucuronide in human plasma by UHPLC-MS/MS.

  2019cites this paper
• Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies

  2019cites this paper
• Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose

  2019cites this paper
• The Place of Community Rescue Naloxone in a Public Health Crisis of Opioid Overdose

  2019cites this paper
• Use of nebulized naloxone to reverse methadone overdose – A case report and review of literature

  2019cites this paper
• High-dose naloxone, an experimental tool uncovering latent sensitisation: pharmacokinetics in humans.

  2019cites this paper
• Deslorelin and naltrexone stimulate follicular development in mares during autumn transition and early anestrus.

  2019cites this paper
• The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs

  2019cites this paper
• The Opioid Epidemic: Crisis and Solutions.

  2018cites this paper
• A Case of Nebulized Naloxone Use With Confirmatory Serum Naloxone Concentrations

  2018cites this paper
• Naloxone nasal spray (Nyxoid®) in opioid overdose: a profile of its use in the EU

  2018cites this paper
• Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers

  2018cites this paper
• Post-stroke Intranasal (+)-Naloxone Delivery Reduces Microglial Activation and Improves Behavioral Recovery from Ischemic Injury

  2018influential citation
• Clinical Update: The Risk of Opioid Toxicity and Naloxone Use in Operational K9s.

  2018cites this paper
• The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling

  2018cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• Toxicology in Emergency Medicine

  2018cites this paper
• Naloxone nasal spray (Nyxoid®) in opioid overdose: a profile of its use in the EU

  2018cites this paper
• Basic and Advanced EMS Providers Are Equally Effective in Naloxone Administration for Opioid Overdose in Northern New England

  2018cites this paper
• Naloxone dosage for opioid reversal: current evidence and clinical implications

  2018cites this paper
• Opioids

  2018cites this paper
• Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review.

  2018cites this paper
• International patent applications for non‐injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database

  2018cites this paper
• 15 A Primer on Medical Toxicology

  2017cites this paper
• Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis‐generating Small Clinical Studies

  2017cites this paper
• Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study*

  2017influential citation
• Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers

  2017cites this paper
• Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review

  2017cites this paper
• Pharmacokinetics of a new, nasal formulation of naloxone

  2017cites this paper
• When to Pick the Nose: Out‐of‐Hospital and Emergency Department Intranasal Administration of Medications

  2017cites this paper
• Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing

  2017cites this paper
• Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems

  2017cites this paper
• Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post‐dosing: analysis of suitability for opioid overdose reversal

  2017cites this paper
• Annual Review of Pharmacology and Toxicology The Opioid Epidemic : Crisis and Solutions

  2017cites this paper
• COMPARISON OF EFFECTS AND SIDE EFFECTS OF TWO NALOXONE-BASED REGIMENS IN TREATMENT OF METHADONE OVERDOSE

  2016cites this paper
• Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?

  2016cites this paper
• Effects of target-controlled infusion of high-dose naloxone on pain and hyperalgesia in a human thermal injury model: a study protocol

  2016influential citation
• Pharmacokinetic Properties and Human Use Characteristics of an FDA‐Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose

  2016cites this paper
• Who gets antidotes? choosing the chosen few.

  2016cites this paper
• President's message: Food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: What is a treatment advocate and educator to do?

  2016cites this paper
• Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception

  2016cites this paper
• Design of freeze-dried formulations for the enhancement of drug release

  2016cites this paper
• Challenges and Opportunities with Predicting In Vivo Phase II Metabolism via Glucuronidation From In Vitro Data

  2016cites this paper
• Development of non-injectable naloxone for pre-hospital reversal of opioid overdoses: A Norwegian project and a review of international status

  2016cites this paper
• Overdose aux opioïdes : présentation clinique et place de la naloxone

  2016cites this paper
• REVIEW-THEMED ISSUE Who gets antidotes? choosing the chosen few

  2016cites this paper
• Amorphous Formulation and in Vitro Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone.

  2016cites this paper
• Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal.

  2016cites this paper
• Anti-addiction Agents

  2016cites this paper
• Tangled-up and blue: releasing the regulatory chokehold on take-home naloxone.

  2016cites this paper
• Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review

  2015cites this paper
• Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access

  2015cites this paper
• Compositions de naloxone intranasales et leurs procédés de préparation et d'utilisation

  2014cites this paper
• Intranasal naloxone administration for treatment of opioid overdose.

  2014cites this paper
• Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial

  2014cites this paper
• Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users

  2014cites this paper
• ACMDCouncil on the Misuse of Drugs

  2014cites this paper
• Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients

  2013cites this paper
• Paracetamol and opioid pathways: a pilot randomized clinical trial

  2013cites this paper
• Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.

  2013cites this paper
• Use and efficacy of nebulized naloxone in patients with suspected opioid intoxication.

  2013cites this paper
• Pre-hospital management and outcome of acute poisonings by ambulances in Yekaterinburg, Russia

  2013cites this paper
• Comment on “Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients”

  2013cites this paper
• Formes dosifiees pharmaceutiques intranasales comprenant de la naloxone

  2012cites this paper
• A response to the opioid overdose epidemic: naloxone nasal spray

  2012influential citation
• Drug discovery and development: lessons from an undeveloped drug

  2012cites this paper
• Management of opioid analgesic overdose.

  2012cites this paper
• Management of opioid analgesic overdose.

  2012cites this paper
• Facilitating medical withdrawal from opiates in rural Ontario.

  2012cites this paper